Detalhe da pesquisa
1.
Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity.
Cancer Immunol Immunother
; 70(4): 909-921, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33037893
2.
Immunotherapy With Low-Dose IL-2/CD25 Prevents ß-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice.
Diabetes
; 72(6): 769-780, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36939730
3.
Engineering IL-2 for immunotherapy of autoimmunity and cancer.
Nat Rev Immunol
; 22(10): 614-628, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35217787